<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516828</url>
  </required_header>
  <id_info>
    <org_study_id>I186</org_study_id>
    <secondary_id>CAN-NCIC-IND186</secondary_id>
    <secondary_id>CDR0000560975</secondary_id>
    <nct_id>NCT00516828</nct_id>
  </id_info>
  <brief_title>Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth or by blocking blood flow to the cancer. Drugs used in chemotherapy,&#xD;
      such as cytarabine, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving sorafenib together with&#xD;
      cytarabine may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib&#xD;
      together with cytarabine and to see how well it works in treating older patients with acute&#xD;
      myeloid leukemia or high-risk myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the recommended dose of sorafenib tosylate and cytarabine when given in&#xD;
           combination to elderly patients with acute myeloid leukemia or high-risk myelodysplastic&#xD;
           syndromes who are not suitable for intensive chemotherapy. (Phase I)&#xD;
&#xD;
        -  To determine the safety, tolerability, toxicity profile, and dose-limiting toxicities in&#xD;
           patients treated with this regimen. (Phase I)&#xD;
&#xD;
        -  To estimate the efficacy (as measured by complete response rate) in patients treated&#xD;
           with this regimen. (Phase II)&#xD;
&#xD;
        -  To describe the toxic effects and overall response rate (complete and partial) in&#xD;
           patients treated with this regimen. (Phase II)&#xD;
&#xD;
        -  To evaluate potential correlates of response in translational research studies including&#xD;
           FLT-3 internal tandem duplications and point mutations in blasts. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Phase I: Patients receive oral sorafenib tosylate twice daily on days 2-28 and&#xD;
           cytarabine subcutaneously twice daily on days 1-10 at the dose level assigned at&#xD;
           registration. Doses of both drugs will be escalated and the recommended doses for the&#xD;
           combination will be determined. Treatment repeats every 28 days for up to 6 courses in&#xD;
           the absence of disease progression or unacceptable toxicity. Patients who respond to&#xD;
           treatment will receive 2 cycles after response criteria are met.&#xD;
&#xD;
        -  Phase II: Patients receive sorafenib tosylate and cytarabine as in phase I at the&#xD;
           recommended doses for the combination determined in phase I.&#xD;
&#xD;
      Bone marrow (or blood) samples are collected at baseline and at the end of each course of&#xD;
      study treatment. Baseline samples are analyzed for mutational status of FLT-3 (i.e., internal&#xD;
      tandem duplication [ITD] and point mutations).&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3 months&#xD;
      thereafter until progression and toxicities resolve.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2007</start_date>
  <completion_date type="Actual">January 10, 2013</completion_date>
  <primary_completion_date type="Actual">March 18, 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose of sorafenib tosylate when given in combination with cytarabine (Phase I)</measure>
    <time_frame>29 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (Phase I)</measure>
    <time_frame>29 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (Phase II)</measure>
    <time_frame>29 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (complete and partial response) (Phase II)</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (Phase II)</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FLT-3 ITD endpoint mutation response correlation.</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (Phase II)</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Sorafenib and Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>subcutaneously twice daily from Day 1 to 10</description>
    <arm_group_label>Sorafenib and Cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) by FAB criteria (By morphology and routine&#xD;
                  histochemistry and confirmed, when possible, by flow cytometric analysis of&#xD;
                  surface immunophenotype; co-expression of lymphoid markers permitted)&#xD;
&#xD;
               -  High-risk myelodysplastic syndromes defined as IPSS category of intermediate-2 or&#xD;
                  greater&#xD;
&#xD;
          -  Must be considered unsuitable for intensive chemotherapy regimens&#xD;
&#xD;
          -  No documented CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine ≤ 1.2 times ULN OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer,&#xD;
             curatively treated in situ carcinoma of the cervix, or other solid tumors curatively&#xD;
             treated with no evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  No upper gastrointestinal or other conditions that would preclude compliance with or&#xD;
             administration of oral medication&#xD;
&#xD;
          -  No serious illness or medical condition that would not permit the patient to be&#xD;
             managed according to the protocol, including any of the following:&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorder that would impair the&#xD;
                  ability to obtain consent&#xD;
&#xD;
               -  Active, uncontrolled, serious infections&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Evidence of bleeding diathesis&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No active cardiomyopathy or unstable ventricular arrhythmia&#xD;
&#xD;
          -  No poorly controlled hypertension (e.g., systolic BP ≥ 150 mm Hg or diastolic BP ≥ 95&#xD;
             mm Hg)&#xD;
&#xD;
          -  No known hypersensitivity to the study drugs or their components&#xD;
&#xD;
          -  No preexisting hypothyroidism prior to enrollment unless patient is euthyroid on&#xD;
             medication&#xD;
&#xD;
          -  No neuropathy ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 2 days since prior hydroxyurea&#xD;
&#xD;
          -  No other prior chemotherapy&#xD;
&#xD;
          -  No concurrent therapeutic doses (≥ 2 mg/day) of anticoagulants (e.g., warfarin)&#xD;
&#xD;
               -  Doses of up to 2 mg/day given for prophylaxis of thrombosis are accepted provided&#xD;
                  INR is ≤ 1.5&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Leber, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>McMaster Children's Hospital at Hamilton Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A. MacDonald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nova Scotia Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Macdonal DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Foo A, Leber B. Phase I/II study of low-dose cytarabine with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome. J Clin Oncology 28[15s, abstr 6564]. 2010.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

